1	Title: Comparison of Peripheral Nerve Injury Outcomes Between COVID-19 Survivors and Non-COVID
2	Rehabilitation Inpatients: A Retrospective Study
3	
4	Authors: Antonio Mondríguez-González MD* ^a ; Brian M. Rothemich* BS ^b ; Manasi Sheth PhD ^{a1} ; Kevin N.
5	Swong ^c ; Colin K. Franz MD, PhD ^{a, d, e, f}
6	a. Shirley Ryan Ability Lab: 355 E. Erie St, Chicago, IL 60611, USA
7	b. Virginia Commonwealth University School of Medicine: 1201 E Marshall St #4-100, Richmond,
8	VA 23298, USA
9	c. Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine: 420
10	E Superior St, Chicago, IL 60611, USA
11	d. Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of
12	Medicine, Chicago IL: 420 E Superior St, Chicago, IL 60611, USA
13	e. Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of
14	Medicine, Chicago IL: 420 E Superior St, Chicago, IL 60611, USA
15	f. Querrey Simpson Institute for Bioelectronics, Northwestern University Feinberg School of
16	Medicine, Chicago IL: 303 E. Superior St, Chicago, IL 60611, USA
17	*, denotes equal contribution by authors
18	
19	Short Running Title: COVID-19 vs. Non-COVID PNI Outcomes
20	Corresponding Author: Colin K. Franz, Shirley Ryan AbilityLab, 26-North, 355 E. Erie Street, Chicago,
21	IL 60611, USA; cfranz@sralab.org
22	
23	
24	

¹ Permanent address: 351 Evergreen Circle, Glendale Heights, IL 60139, USA

25 Abstract

- 26 Introduction: Peripheral nerve injury (PNI) is associated with severe Coronavirus disease 2019 (COVID-
- 27 19) survivorship. The diagnosis of PNI is often made by a physiatrist during a detailed functional
- 28 assessment during an inpatient rehabilitation stay. COVID-19 patients have elevated rates of medical
- 29 comorbidities, including risk factors for acquired PNI, such as diabetes mellitus and obesity. It is not
- 30 known if the functional prognosis from PNI in COVID-19 survivors differs substantially from PNI in other
- 31 inpatient rehabilitation populations.
- 32 **Objective:** To determine the prognosis of PNI associated with severe COVID-19 survivorship and
- 33 compare it to PNI associated with other inpatient rehabilitation populations.
- 34 **Design:** Retrospective chart review study.
- 35 Setting: Single-center inpatient rehabilitation hospital in a large urban city.
- 36 Patients: Adult patients admitted to an inpatient rehabilitation hospital with PNI(s).
- 37 Interventions: Not applicable.
- 38 Main Outcome Measures: The primary outcome was the change in manual muscle testing (MMT) over
- time. Secondary outcomes included the rate of peripheral nerve surgery and the number of distinct PNI

40 sites per patient.

- 41 **Results:** The analysis consisted of 60 subjects with PNI. We identified 30 subjects who had PNI
- 42 associated with COVID-19 and were matched with 30 subjects with PNI not associated with COVID-19
- 43 who were diagnosed during their inpatient rehabilitation admission. The data collected included basic
- 44 demographics, COVID-19 status immediately before inpatient rehabilitation admission, medical
- 45 comorbidities, acute rehabilitation inpatient diagnosis, nerve injury location and mechanism of injury,
- 46 muscles affected, and change in serial MMT, plus documentation of any surgical intervention. No
- 47 significant difference was found between the improvement of MMT, surgery rate, or number of nerve
- 48 injuries and COVID-19 status.
- 49 Conclusion: PNIs associated with severe COVID-19 survivorship have similar recovery patterns as those
- 50 of other etiologies. This data is reassuring that PNI associated with COVID-19 may be managed similarly
- 51 to other types of PNI.

53 Introduction

54 Coronavirus disease 2019 (COVID-19) has profoundly affected the world's health. As of August 2024, 55 there have been 776 million confirmed disease cases.¹ Furthermore, multiple studies suggest that 56 survivorship issues from COVID-19 include an array of PNIs. Overall, although a variety of risk factors 57 have been associated with acquired PNI from severe COVID-19, little is known about the clinical 58 outcomes of these patients. To make matters worse, COVID-19 has been associated with multiple 59 mononeuropathies in the same patient. For example, our group recently described a case series involving 60 66 PNIs found in 34 patients (average ~2 PNI/patient).² This association of PNI with COVID-19 61 survivorship was noted early in the pandemic, including an observation that 12/83 post-COVID-19 62 patients consecutively admitted for inpatient rehabilitation had an acquired PNI,² and just a few weeks 63 later, a separate group described mononeuritis multiplex patterns in 11/69 COVID-19 patients 64 consecutively admitted to an intensive care unit (ICU).³ Irrespective to the COVID-19 pandemic, the rates 65 of PNI worldwide are ill-defined. Still, the best estimates come from developed countries with national 66 healthcare registries with rates between 11 to 14 cases per 100,000 population per year.45 This is likely an 67 underestimation of PNI incidence. For example, PNI can be an under-reported complication in the 68 perioperative setting, overlooked or missed in cases of complex polytrauma, and in many countries like 69 the United States that lack a national registry to study PNI; there are higher rates of PNI from gun 70 violence.[®] Outcomes from PNI are known to be highly variable regardless of whether patients undergo 71 nerve repair surgery.[®] Therefore, it is often challenging to prognosticate patient outcomes accurately. Prior 72 studies have implicated age, site of injury, type of injury, and extent of vascular damage as the most 73 important factors.89

Given the large numbers of people who survived severe COVID-19 and consequently were exposed to this risk for acquiring a PNI, the question of whether or not PNI outcomes are worse in survivors of severe COVID-19 is both important and unanswered. The purpose of this retrospective chart review study is to begin to define neurological recovery patterns and prognosis of PNIs associated with severe COVID-19 versus other non-COVID-19 associations. Since we have access to a relatively large and chronic series of patients who acquired PNI in association with admission for acute COVID-19, we performed a retrospective study to compare their recovery patterns and outcomes in follow-up against those of non-

- 81 COVID-19 associated PNI identified from inpatient rehabilitation patients diagnosed and treated in an
- 82 overlapping time frame.
- 83 Materials and Methods
- 84 Study Subjects

85 Study approval was granted by the Northwestern University Institutional Review Board. A total of 60 86 subjects with a diagnosis of PNI were included in this study. PNI in the context of this study is defined as 87 mononeuropathy caused by traumatic etiologies such as gunshots, puncture wounds, and high-impact 88 collisions and nontraumatic etiologies such as entrapment/compression, critical illness, severe COVID-19 89 survivorship, or medications leading to an impact on muscle strength and motor function. Subjects were 90 selected from a registry of known PNI cases treated at the Shirley Ryan AbilityLab (an academic 91 freestanding inpatient rehabilitation facility) in Chicago, IL (USA). Furthermore, subjects included in this 92 study were equal to or greater than 18 years of age, and their PNI(s) must have been supported by 93 electrodiagnostic studies. All subjects were patients admitted to inpatient rehabilitation who had their 94 initial electrodiagnostic study and MMT conducted upon their rehabilitation hospital admission prior to 95 their PNI being diagnosed. Subjects were placed into the post-COVID-19 PNI group if they acquired 96 PNI(s) after admission to an acute care hospital for severe COVID-19 pneumonia. The post-COVID-19 97 PNI group was admitted to inpatient rehabilitation due to generalized weakness and deconditioning as a 98 result of severe COVID-19 survivorship and its associated hospital complications. Severe COVID-19 99 survivorship was defined as recovery from an acute care hospitalization for COVID-19 requiring the use 100 of assistive respiratory devices. Patients who were under the age of 18 or did not fit the rest of the 101 inclusion criteria were excluded from data collection.

102 Study Outcomes

103 The primary outcome of this retrospective study is to compare the improvement of MMT from the initial 104 diagnosis and after-treatment interventions.¹⁰ MMT was selected since it was well documented across 105 patient charts and is a common clinical metric of peripheral nerve health. We were concerned that the 106 improvement in MMT will be less in the post-COVID-19 group compared to other inpatient rehabilitation patients (control group) due to the severity of their preceding illness, thus indicating a slower or reduced recovery process. The secondary outcome is to compare the surgery rate between these two groups. Due to the high rate of severe (axonotmesis) PNI associated with COVID-19,² we wondered if there may be a higher rate of nerve repair surgery within the post-COVID-19 group. The other secondary outcome is to compare the number of concomitant sites of PNI between the two groups. Since COVID-19 has been associated with mononeuritis multiplex patterns, we predicted that the post-COVID-19 group would be diagnosed with significantly more PNIs per patient.

114 Data Collection

115 Data was collected by retrospectively reviewing patients' electronic medical records with PNI from July 116 2018 to September 2023. A combination of electronic medical records from internal and external hospital 117 systems was used to collect thorough data. We recorded several data points for each subject that 118 consisted of age, race/ethnicity, whether or not the patient had COVID-19 before the PNI, comorbidities, 119 acute rehabilitation inpatient status, mechanism of PNI, location of PNI, type of treatment intervention, 120 electrodiagnostic studies at diagnosis, muscles affected by the PNI and their associated MMT scores at 121 diagnosis and after treatment intervention. Each subject was screened for the following illnesses: 122 diabetes mellitus, B12 deficiency, hypertension, hyperlipidemia, and obesity. The type of treatment was 123 subdivided into no surgery, external neurolysis, direct nerve repair, nerve graft repair, and nerve transfer 124 surgery. MMT grades were recorded with the standard 0-5 scale without modifiers (i.e., no 4+ or 4-). Only 125 muscles tested during a documented physical exam and graded less than five were recorded at or within 126 a month after initial electrodiagnostic studies. Follow-up MMT was done within 1 month of initial 127 electrodiagnostic testing at either an outpatient or inpatient setting, depending on if the patient had been 128 discharged from inpatient rehabilitation, although the latest available MMT was recorded for post-129 intervention data points within a maximum of two years of the start of the intervention (physical therapy, 130 surgery).

131

133 Data Preparation

134 When analyzing MMT data, the 60 subjects were further broken down into the specific nerve-injured and 135 the associated muscle groups innervated by the nerve. Each nerve was then listed with its associated 136 pre-intervention and post-intervention MMT grades. Each PNI was then categorized into one of three 137 groups: no improvement, small improvement, and large improvement. No improvement was given if the 138 difference in muscle grades was "0". Small improvement was given if the muscle grade improved by one 139 MMT grade, except for a "4," progressing into a "5" to mitigate against the ceiling effect. Large 140 improvement was given if the muscle grade improved to a "5" or improved by two or more MMT grades. 141 Furthermore, if a PNI was not confirmed by a corresponding muscle group with a pre-intervention and 142 post-intervention manual muscle test, it was removed from the data set (e.g., lateral femoral cutaneous 143 nerve). In addition, if two or more muscle groups were associated with the PNI, only the muscle group 144 with the highest level of improvement was included in the data set. If there was a tie in improvement level, 145 then the most proximal muscle group with respect to the lesion site was included in the data set when 146 paired with the PNI.

147

148 Statistical Analysis

149 Following data collection and preparation, a Student's t-test and several two-sided Fisher's exact tests

150 were appropriately used to determine the presence of a statistically significant difference between ages,

151 sex, race/ethnicities, comorbidities, and mechanism of injury for the post-COVID-19 PNI versus other

152 non-COVID-19 PNI. A p-value of 0.05 was used when testing the statistical significance.

A Mann-Whitney U test was used to evaluate whether improvement in strength grading from MMT (no improvement, small improvement, large improvement) significantly differs by the COVID-19 status of PNI (post-COVID-19 versus other non-COVID-19 associations). A p-value of 0.05 was used when testing the statistical significance.

157 A two-sided Fisher's exact test was used to determine if there was a significant association between 158 treatment intervention and the COVID-19 status of PNI. A 2x2 contingency table was made to record the 159 number of observations for treatment intervention (surgery versus no surgery) and the COVID-19 status 160 of PNI (post-COVID-19 versus other non-COVID-19 associations). A p-value of 0.05 was used when 161 testing the statistical significance. 162 A two-sided Fisher's exact test was used to determine if there was a significant association between the 163 number of PNIs and post-COVID-19 status. A 2x2 contingency table was created to record the number of 164 observations for each group. A p-value of 0.05 was used when testing the statistical significance. 165 IRB and Data Storage 166 This research study was approved by the Northwestern University IRB before data collection. Since this 167 project is a retrospective chart review with no contact with subjects, no informed consent or waiver of 168 consent was needed to gather and conduct research. All data documents with patient identifiers were

169 encrypted and only available to the study investigators. All data was initially entered into a password-

170 protected RedCap project database without patient identifiers. Before statistical analysis, all patient

171 identifiers were removed from the final data collection document.

172

173 Results

174 Demographics, Comorbidities, and Mechanism of Nerve Injury

A total of 60 subjects were analyzed in this study. Of these patients with PNIs, 30 subjects belong to the post-COVID-19 PNI group, while the remaining 30 subjects with other non-COVID-19 PNI belong to the control group. A summary of their characteristics can be seen in Table 1. Statistically significant differences were noted between the post-COVID-19 PNI group and the control group in the prevalence of diabetes (COVID n=19/30, non-COVID-19 3/30, p=0.0001), and hypertension (COVID n=22/30, non-COVID-19 8/30, p=0.0007). In addition, other statistically significant differences were found between the post-COVID-19 PNI group and the control group in the ages (COVID 55.9±12.2, non-COVID-19

43.2±16.2, p=0.001), and the Hispanic White racial/ethnicity group (COVID n=11/30, non-COVID-19 2/30,
p=0.010). Lastly, the ratios of the mechanism of injury when comparing traumatic versus nontraumatic
injuries proved to be statistically significant (COVID 0:30, non-COVID-19 19:11, p=0.0001). The ratios
between sex, the remaining racial/ethnic groups, and obesity failed to reject the null hypothesis.

186 MMT Comparison Results

187 Improvements in MMT data are summarized in Figure 1A. A Mann-Whitney U test was used to evaluate

188 whether improvement in strength grading from MMT (no improvement, small improvement, large

189 improvement) significantly differs by the COVID-19 status of PNI (post-COVID-19 versus other non-

190 COVID-19 associations). The null hypothesis stated no significant difference exists between the

191 improvements in manual muscle tests and the COVID-19 status of PNI. The results indicated no

192 significant difference between the improvement in manual muscle tests and the COVID-19 status of PNI

193 (z = 1.5195, p = 0.1285).

194 Surgery Comparison Results

195 Surgical intervention data for each subject's PNI(s) is displayed in Table 1 and summarized in Figure 1B. 196 We predicted that there would be a significantly higher surgery rate within the post-COVID-19 group, thus 197 indicating that they require a more complicated recovery process due to the severity of the injuries. A 198 Fisher's exact test was conducted to test the prediction that a significant association exists between 199 treatment intervention and the COVID-19 status of PNI. The null hypothesis stated that no significant 200 association exists between treatment intervention and the COVID-19 status of PNI. Using a 0.05 alpha, 201 the null hypothesis failed to be rejected (two-tailed p = 0.1188). Therefore, there is no significant 202 association between treatment intervention (no surgery versus surgery) and the COVID-19 status of PNI 203 (post-COVID-19 versus other non-COVID-19 associations).

204 Number of Nerve Injuries Comparison Results

The number of nerve injuries for each subject is shown in Table 1 and summarized in Figure 1C. We predicted that there would be a significantly higher number of PNIs within the post-COVID-19 group. A Fisher's exact test was conducted as outlined in the Materials and Methods section to test this prediction that there is a significant association between the number of PNIs and the COVID-19 status of the PNI. The null hypothesis stated that no significant association exists between the number of PNIs and the COVID-19 status of the PNI. Using a 0.05 alpha, the null hypothesis failed to be rejected (two-tailed p = 0.1188). Therefore, there is no significant association between the number of PNIs (one injury versus multiple injuries) and the COVID-19 status of the PNI (post-COVID-19 versus other non-COVID-19 associations).

214 Discussion

215 Severe COVID-19 survivorship is associated with PNIs. Many of these COVID-19-associated PNIs tend 216 to be severe, primarily associated with axonal injuries, and even with proper medical care, lead to 217 significant disability in many patients.² This prior data implied that COVID-19-associated PNIs may have 218 less favorable outcomes than other types of PNIs. Upon initial evaluation, the COVID-19 PNI group had a 219 statistically significant older sample and a higher presence of comorbidities such as diabetes and 220 hypertension, as seen in Table 1. Older age, diabetes, and hypertension are risk factors for developing 221 PNIs, while older age is a risk factor for poorer PNI prognosis.⁹ However, our retrospective analysis 222 revealed no significant associations between improvement in MMT and whether or not the PNI was 223 associated with COVID-19. Our findings reassure us that COVID-19-associated PNI patients do not have 224 substantially different outcomes. In addition, there were no differences in the need for surgical 225 intervention or the number of PNI sites/patients and COVID-19. Together, these results indicate COVID-226 19 COVID-19-associated PNI patients do not appear to have inherently worse outcomes than non-227 COVID-19 PNI patients. These results support using existing treatment guidelines for PNIs in this specific 228 patient population.

Severe COVID-19 patients appear to have an increased propensity for acquired PNI, and the potential reasons for this are likely multifactorial. Although the data is limited, in one neuropathological study of patients who died from COVID-19, muscle and nerve tissues exhibited signs of immune-mediated damage without direct infection by SARS-CoV-2, underscoring the impact of immune response rather than viral invasion in nerve injuries associated with the disease." It appears that an interplay of

inflammatory and other immune-mediated factors results in a cytokine storm that directly damages nerve
tissue and supporting vasculature,^{12,13,14,15} combined with mechanical loading of nerves due to patient
positioning while admitted in the ICU.^{16,17,18} Indeed, our group previously noted that PNI localizations
seemed heavily biased to sites of known vulnerability to mechanical loading from direct compression or
traction mechanisms.²

239 PNI management can vary depending on whether they are open or closed injuries. Open injuries from 240 traumatic mechanisms such as laceration or transection generally benefit from early surgical repair (re-241 anastomosis, grafting, etc.) when they are identified acutely. Meanwhile, closed injuries can be due to 242 more diverse etiologies, from non-penetrating traumatic injury to chronic nerve entrapment injury, such as 243 carpal tunnel syndrome.¹⁹ Generally speaking, COVID-19-associated PNIs are closed injuries. Closed 244 injuries require a thorough clinical assessment, usually including electrodiagnostic studies and serial 245 reassessments, which can include advanced imaging with repeat electrodiagnostic studies and physical 246 examination. If a closed PNI shows no signs of spontaneous axon regeneration, then patients may 247 consider whether or not to undergo surgery, which may involve repair methods such as neurolysis, 248 neuroma resection, and/or graft repair, as well as nerve transfer surgery.¹⁹ Physical and/or occupational 249 therapy is an essential part of the pre-habilitation and post-surgical rehabilitation process. Interestingly, 250 despite the non-COVID-19 PNI group of our study containing many more traumatic mechanisms of injury, 251 the rate of surgery used to manage these two patient groups was not statistically different. The 252 significance of this finding is uncertain, given the retrospective nature of our study.

253 Since the recovery of COVID-19 patients with PNIs does not differ substantially from the control group, it 254 appears that similar treatment algorithms may be applied to both groups. In addition to reinforcing current 255 guidelines on PNI treatment management for severe COVID-19 survivors, this study should help 256 rehabilitation physicians evaluate the prognosis of post-COVID-19 patients with PNIs. This study's findings 257 suggest no difference in muscle strength recovery regardless of the mechanism of injury and association 258 with severe COVID-19 survivorship. Ninety-two percent of patients with COVID-19-associated PNI gained 259 back some level of muscle improvement, while 75% of other causes of PNI improved in motor deficits. A 260 majority of patients experiencing motor improvement after PNI treatments is not unexpected and is in line

261 with multiple prior studies. For example, Kim et al. demonstrate that 73% of patients with thoracic outlet 262 syndrome-associated motor deficits improved after appropriate treatment.[®] Furthermore, another study with 263 107 patients with a variety of upper limb PNIs had a statistically significant improvement in all 107 patients' 264 muscle strength after appropriate treatment.²⁰ Despite state-of-the-art treatments being made available to 265 all PNI patients in this study, functional recoveries were near-universally incomplete.²⁸ Partial functional 266 recovery of PNIs remains a significant burden of disability of post-ICU survivors, including those that 267 develop PNIs after severe COVID-19 survivorship.²¹ Although these PNIs associated with COVID-19 268 remain primarily axonal,² no FDA-approved treatments are available to improve axon regeneration in this 269 patient population. More clinical research should be conducted to find effective axonal regeneration 270 treatments to reduce the functional disability of these patients.

271 Evaluation of the study samples revealed possible health disparities due to the overrepresentation of a 272 socially disadvantaged population. In the COVID-19-associated PNI sample, the distribution of 273 race/ethnicity was 33.3%, 23.3%, and 36.7% for non-Hispanic white, non-Hispanic Black/African 274 American, and Hispanic white, respectively. According to the 2018-2022 United States Census, Chicago's 275 distribution of race/ethnicity was 32.7%, 28.8%, and 29.0% for non-Hispanic white, non-Hispanic 276 Black/African American, and Hispanic white, respectively.²² The data demonstrates a large 277 overrepresentation of patients who identify as Hispanic white in the severe COVID-19 PNI group. As seen 278 in Table 1, a statistical analysis confirmed an overrepresentation of people who identify as Hispanic white 279 in the COVID-19 PNI group. This overrepresentation could be due to a variety of factors. The Hispanic 280 population in Chicago was the most likely ethnic group to work in essential and high-exposure jobs during 281 the COVID-19 pandemic.²³ In addition, there are social and economic factors within this ethnic group that 282 reduce their access to healthcare, thus increasing their chances of developing complications due to 283 severe COVID-19 survivorship.²⁴These risk factors and health disparities affiliated with COVID-19-284 associated PNI can be further investigated in a subsequent study.

It is important to recognize the scope of clinical impact this study has regarding the increased prevalence of PNIs in the study population. The rate of focal neuropathies associated with severe COVID-19 survivorship at inpatient rehabilitation facilities is approximately 10% compared to approximately 0.5% in

general rehab patients over the same time period.² PNIs subject patients to a substantial amount of longterm disability due to sensorimotor deficits and chronic neuropathic pain. Considering the high prevalence of PNIs associated with COVID-19 in the inpatient rehabilitation setting, physicians can implement the results from this study by confirming the effectiveness of their own clinical practices and existing treatment guidelines for addressing PNIs.

293 Limitations

294 The limitations need to be addressed before considering the full implications of this study. There is a 295 relatively small sample of 60 subjects used in this study due to the limited number of qualifying subjects 296 from a single healthcare facility. Both the smaller sample size and the location where the sample was 297 collected reduce external validity; however, this study is still the largest single data set to report COVID-298 19 PNI long-term outcomes. In addition, since patient follow-ups occurred inconsistently and at varied 299 time frames, the post-treatment MMT data was collected at different time intervals among the patients. 300 Selection bias resulted from several patients or multiple muscle groups not being included in the MMT 301 data analysis due to incomplete follow-up data. Incomplete follow-up data either resulted from patients 302 not returning for follow-up visits entirely or follow-up visits only containing partial MMT data compared to 303 their initial visit. These issues could potentially introduce bias by disproportionately increasing or 304 decreasing the improvement in MMT for one or both groups. Lastly, due to the retrospective design of this 305 study, outcome data for muscle strength improvement was limited to an outcome measure that is used 306 routinely in clinical practice, such as MMT, rather than more objective and continuous data, such as 307 torque production or electrophysical recordings.

308 Future Works

309 Several of these limitations can be addressed in future extensions of this study. For example, a larger 310 sample size could increase the power of the results. The inclusion of multiple hospital systems, such as 311 collaboration with other hospitals within our geographical region, could increase the external validity of the 312 results. Furthermore, we hope to include phrenic neuropathy data in future iterations of this study by 313 tracking improvements in diaphragm thickness ratios. Lastly, a multivariable regression analysis might

- reveal complex associations not outlined in this paper, such as manual muscle improvement associated
- 315 with race, gender, number of nerve injuries, treatment intervention, and COVID-19 status of nerve injury.

316 Conclusion

- 317 This data is impactful to the medical community as there is no literature to our knowledge that outlines the
- prognosis of this particular study population. This research fills a gap in the literature by providing a better
- 319 understanding of the prognosis of post-COVID-19 PNIs. Because the results suggest there is no
- 320 significant difference in prognosis between PNIs and their COVID-19 status, it can be inferred that
- 321 physicians should not treat the two groups differently.

322			
323			
324			
325			
326			
327			
328			
329			
330			
550			
224			
331			
332			
333			
334			
554			
335			
336			
337			
338			
220			
339			

340 References

341	1.	WHO Coronavirus (COVID-19) Dashboard. Accessed August 21, 2024. https://covid19.who.int
342	2.	Franz CK, Murthy NK, Malik GR, et al. The distribution of acquired peripheral nerve injuries
343		associated with severe COVID-19 implicate a mechanism of entrapment neuropathy: a
344		multicenter case series and clinical feasibility study of a wearable, wireless pressure sensor. J
345		NeuroEngineering Rehabil. 2022;19(1):108. doi:10.1186/s12984-022-01089-1
346	3.	Needham E, Newcombe V, Michell A, Thornton R, Grainger A, Anwar F, Warburton E, Menon D,
347		Trivedi M, Sawcer S. Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-
348		19. J Neurol. 2021 Aug;268(8):2685-2689. doi: 10.1007/s00415-020-10321-8. Epub 2020 Nov 26.
349		PMID: 33244712; PMCID: PMC7690651.
350	4.	Murphy RNA, de Schoulepnikoff C, Chen JHC, et al. The incidence and management of
351		peripheral nerve injury in England (2005-2020). J Plast Reconstr Aesthet Surg. 2023;80:75-85.
352		doi:10.1016/j.bjps.2023.02.017
353	5.	Asplund M, Nilsson M, Jacobsson A, von Holst H. Incidence of traumatic peripheral nerve injuries
354		and amputations in Sweden between 1998 and 2006. Neuroepidemiology. 2009;32(3):217-228.
355		doi:10.1159/000197900
356	6.	Welch MB, Brummett CM, Welch TD, et al. Perioperative peripheral nerve injuries: a retrospective
357		study of 380,680 cases during a 10-year period at a single institution. Anesthesiology.
358		2009;111(3):490-497.doi:10.1097/ALN.0b013e3181af61cb
359	7.	Stone L, Keenan MA. Peripheral nerve injuries in the adult with traumatic brain injury. Clin Orthop
360		Relat Res. 1988;(233):136-144.
361	8.	Kim DH, Cho YJ, Tiel RL, Kline DG. Outcomes of surgery in 1019 brachial plexus lesions treated
362		at Louisiana State University Health Sciences Center. J Neurosurg. 2003;98(5):1005-1016.
363		doi:10.3171/jns.2003.98.5.1005
364	9.	Hundepool CA, Ultee J, Nijhuis TH, Houpt P; Research Group 'ZERO'; Hovius SE. Prognostic
365		factors for outcome after median, ulnar, and combined median-ulnar nerve injuries: a prospective
366		study. J Plast Reconstr Aesthet Surg. 2015 Jan;68(1):1-8. doi: 10.1016/j.bjps.2014.09.043. Epub
367		2014 Sep 28. PMID: 25448370.

368 10. Compston A. Aids to the investigation of peripheral nerve injuries. Medical Research Council:

- 369 Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74
- figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By
- 371 Michael O'Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures.
- 372 Brain. 2010;133(10):2838-2844. doi:10.1093/brain/awq270
- 373 11. Suh J, Mukerji SS, Collens SI, et al. Skeletal Muscle and Peripheral Nerve Histopathology in
 374 COVID-19. *Neurology*. 2021;97(8):e849-e858. doi:10.1212/WNL.00000000012344
- 375 12. Zhang Y, Chen X, Jia L, Zhang Y. Potential mechanism of SARS-CoV-2-associated central and
- peripheral nervous system impairment. Acta Neurol Scand. 2022 Sep;146(3):225-236. doi:

377 10.1111/ane.13657. Epub 2022 Jun 14. PMID: 35699161; PMCID: PMC9349396.

- Tutal Gursoy G, Yuksel H, Mulkem Simsek I, et al. Neurological Presentations in Patients with
 COVID-19 in Cytokine Storm. *Can J Neurol Sci J Can Sci Neurol*.:1-7. doi:10.1017/cjn.2021.247
- 14. Li Z, Liu T, Yang N, et al. Neurological manifestations of patients with COVID-19: potential routes
 of SARS-CoV-2 neuroinvasion from the periphery to the brain. *Front Med.* 2020;14(5):533-541.

382 doi:10.1007/s11684-020-0786-5

- 383 15. De Sanctis P, Doneddu PE, Viganò L, Selmi C, Nobile-Orazio E. Guillain–Barré syndrome
- 384 associated with SARS-CoV-2 infection. A systematic review. *Eur J Neurol.* 2020;27(11):2361-
- 385 2370. doi:10.1111/ene.14462
- 386 16. Malik GR, Wolfe AR, Soriano R, Rydberg L, Wolfe LF, Deshmukh S, Ko JH, Nussbaum RP,
- 387 Dreyer SD, Jayabalan P, Walter JM, Franz CK. Injury-prone: peripheral nerve injuries associated
- 388 with prone positioning for COVID-19-related acute respiratory distress syndrome. Br J Anaesth.
- 389 2020 Dec;125(6):e478-e480. Doi: 10.1016/j.bja.2020.08.045. Epub 2020 Sep 4. PMID:
- 390 32948295; PMCID: PMC7473147
- 391 17. Miller C, O'Sullivan J, Jeffrey J, Power D. Brachial Plexus Neuropathies During the COVID-19
- 392 Pandemic: A Retrospective Case Series of 15 Patients in Critical Care. *Phys Ther.*
- 393 2021;101(1):pzaa191. doi:10.1093/ptj/pzaa191

- 18. Brugliera L, Filippi M, Del Carro U, et al. Nerve Compression Injuries After Prolonged Prone
- 395 Position Ventilation in Patients With SARS-CoV-2: A Case Series. Arch Phys Med Rehabil.
- 396 2021;102(3):359-362. doi:10.1016/j.apmr.2020.10.131
- 397 19. Spinner RJ, Kline DG. Surgery for peripheral nerve and brachial plexus injuries or other nerve
- 398 lesions. *Muscle Nerve*. 2000;23(5):680-695. doi:<u>10.1002/(sici)1097-4598(200005)23:5<680::aid-</u>
- 399 <u>mus4>3.0.co;2-h</u>
- 400 20. Milicin C, Sîrbu E. A comparative study of rehabilitation therapy in traumatic upper limb peripheral
 401 nerve injuries. *NeuroRehabilitation*. 2018;42(1):113-119. doi:10.3233/NRE-172220
- 402 21. Huebner EA, Strittmatter SM. Axon regeneration in the peripheral and central nervous systems.
- 403 Results Probl Cell Differ. 2009;48:339-351. doi:10.1007/400_2009_19
- 404 22. U.S. Census Bureau QuickFacts: Chicago city, Illinois. Accessed December 26, 2023.
- 405 <u>https://www.census.gov/quickfacts/fact/table/chicagocityillinois/HSD410222</u>
- 406 23. Schnake-Mahl AS, Lazo M, Dureja K, Ehtesham N, Bilal U. Racial and ethnic inequities in
 407 occupational exposure across and between US cities. SSM Popul Health. 2021;16:100959.
- 408 doi:<u>10.1016/j.ssmph.2021.100959</u>
- 409 24. Pedraza L, Villela R, Kamatgi V, Cocuzzo K, Correa R, Lisigurski MZ. The Impact of COVID-19 in
- 410 the Latinx Community. HCA Healthc J Med. 3(3):97-104. doi:10.36518/2689-0216.1387

Subject Characteristics	COVID-19	Non-COVID	p-values (sig<0.05
Age	55.9 ± 12.2	43.2 ± 16.2	p=0.001
Sex M:F	26:4 (n=30)	21:9 (n=30)	p=0.209
Race/Ethnicities	Non-Hispanic White 33.3% (10/30)	Non-Hispanic White 60.0% (18/30)	Non-Hispanic White p=0.069
	Non-Hispanic Black/African American 23.3% (7/30)	Non-Hispanic Black/African American 16.7% (5/30)	Non-Hispanic Black/African American: p=0.748
	Hispanic White 36.7% (11/30)	Hispanic White 6.7% (2/30)	Hispanic White: p=0.010
	Unknown 6.7% (2/30)	Unknown 16.7% (5/30)	Unknown: p=0.437
Comorbidities	Diabetes 63.3% (19/30)	Diabetes 10.0% (3/30)	Diabetes: p=0.0001
	Obesity 43.3% (13/30)	Obesity 30.0% (9/30)	Obesity: p=0.422
	Hypertension 73.3% (22/30)	Hypertension 26.7% (8/30)	Hypertension: p=0.0007
Mechanism of Injury Traumatic:Nontraumatic	0:30 (n=30)	19:11 (n=30)	p=0.0001
Traumatic:Nontraumatic			p=0.0001
Traumatic:Nontraumatic	0:30 (n=30)		p=0.0001
Traumatic:Nontraumatic	0:30 (n=30)		p=0.0001
Traumatic:Nontraumatic	0:30 (n=30)		p=0.0001
Traumatic:Nontraumatic	0:30 (n=30)		p=0.0001
Traumatic:Nontraumatic	0:30 (n=30)		p=0.0001
Traumatic:Nontraumatic	0:30 (n=30)		p=0.0001

		<u>Cause of Neuropathy</u>		
1	1MT Improvement	COVID-19 Associated (n=38)	Other Causes (n=36)	
	No Improvement in Muscle Grade	8% n=3	25% n=9	
(a)	Small Improvement in Muscle Grade	16% n=6	17% n=6	
	Large Improvement in Muscle Grade	76% n=29	58% n=21	

		<u>Cause of Neuropathy</u>		
	<u>Treatment</u> Intervention	COVID-19 Associated (n=30)	Other Causes (n=30)	
(b)	No Surgery Treatment Intervention	43% n=13	67% n=20	
(0)	Surgery Treatment Intervention	57% n=17	33% n=10	

		Cause of Neuropathy		
	<u>Number of Nerve</u> <u>Injuries</u>	COVID-19 Associated (n=30)	Other Causes (n=30)	
(c)	One Nerve	33%	57%	
	Injury	n=10	n=17	
(c)	Multiple Nerve	67%	43%	
	Injuries	n=20	n=13	

421

Figure 1. Contingency Tables. (a) MMT Improvement. Small Improvement: increase by one grade;
 Large Improvement: increase to 5/5 or increase by two or more grades. (b) Number of Surgeries. (c)

424 Number of Nerve Injuries.

425

426

Record ID	Age	Sex	Race and Ethnicity	Mechanism of Nerve Injury	COAID	Diabetes	Obesity	Hypertension	Surgical Intervention	Number of Nerve Inpro
1	Over 65	Male	Non Hispanic White	Nontraumatic	Yes	No	Yes	No	Yes	1
2	Over 65	Female	Non-Hispanic White	Nontraumatic	Yes	Yes	Yes	No	Yes	4
3	Over 65	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	No	Yes	Yes	No	2
4	45-54	Male	Hispanic White	Nontraumatic	Yes	Yes	No	No	Yes	4
5	55-64	Male	Hispanic White	Nontraumatic	Yes	Yes	No	Yes	NO	1
6 7	55 61	Male	Non Hispanic White	Nontraumatic	Yes	Yes	Yes	Yes	No	1
	55-64	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	No	No	Yes	No	1
8	55-64	Male	Hispanic White	Nontraumatic	Yes	No	Yca	Yes	Ycs	2
9 10	Over 65 18-24	Female Female	Non Hispanic Black/African American Uspanic White	Nontraumatic Nontraumatic	Yes	Yes Yes	Yes No	Yes No	No No	1
10	55 61	Male	Non Hispanic Black/African Amorican	Nontraumatio	Yes	Yes	No	Yos	No	2
12	45-54	Male	Hispanic White	Nontraumatic	Yes	Yes	No	Yes	Yes	2
13	35-44	Female	Hispanic White	Nontraumatic	Yes	No	Yes	Yes	Yes	1
14	55 61	Male	Non Hispanic Black/African American	Nontraumatic	Ves	Yes	No	Yes	No	3
15	Over 65	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	No	No	No	No	2
16	25-34	Male	Unknown	Nontraumatic	YCS	Yes	Yes	Yes	NO	5
17	55-64	Male	Hispanic White	Nontraumatic	Yes	Yes	Yes	Yes	Yes	6
18	Over 65	Male	Llispanic White	Nontraumatic	Yes	No	Yes	Yes	No	4
19	Over 65	Male	Non Hispanic White	Nontraumatic	Yes	Nu	No	Nu	No	1
20	Over 65	Male	Hispanic White	Nontraumatic	Yes	No	No	Yes	Yes	3
21	45-54	Male	Hispanic White	Nontraumatic	Ycs	Yes	No	Yes	No	2
22	25 34	Male	Hispanic White	Nontraumatic	Yes	No	Yes	Yes	No	1
23	Over 65	Female	Non-Hispanic Black/African American	Nontraumatic	No	No	Yes	Yes	No	2
24	45-54	Female	Non-Hispanic White	Nontraumatic	No	No	No	Yes	No	2
25	45-54	Male	Non-Hispanic White	Traumatic	No	No	Yes	Yes	No	1
26	18-24	Male	Hispanic White	Nontraumatic	No	No	No	No	Yes	1
27	18 24	Female	Non Hispanic White	Traumatic	No	No	No	No	Yes	1
28	55-64	Female	Non-Hispanic White	Nontraumatic:	No	No	No	Yes	Yes	1
29	35-44	Male	Non-Hispanic White	Traumatic	No	Yes	No	No	Yes	4
30	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	INO	Yes	No	4
31	45-54	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	No	No	Yes	7
32	Over 65	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	Yes	No	Yes	Yes	1
33	45-54	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	No	Yes	No	2
34	55-64	Male	Non-Hispanic White	Nontraumatic	No	No	No	No	Yes	4
35	55-64	Male	Non-Hispanie White	Nontraumatic	No	No	No	No	Yes	5
36	Over 65	Male	Non-Hispanie White	Nontraumatic	Yes	Yes	Yes	Yes	Yes	3
37	25-34	Male	Non-Hispanic White	Traumatic	No	No	No	Yes	No	1
38	35-44	Male	Non-Hispanic Black/African American	Traumatic	No	No	No	No	No	1
39	35-44	Male	Non-Hispanic White	Traumatic	No	No	No	No	No	3
40 41	18-24 18-24	Female Male	Non-Hispanie White	Traumatic Traumatic	No No	No No	No No	No Nu	No No	1
41 42			Non-Hispanic Black/African American				No Yes	No	No	3
42.	Over 65 25 34	Male Male	Non-Hispanic White Non Hispanic Black/African American	Traumatic Traumatic	No No	No No	Yes No	No	No	1
44	25-34	Male	Hispanic Black/Airtean American Hispanic White	Traumatic	No	No	No	No	No	1
44	35-44	Male	Unknown	Traumatic	No	No	Yes	No	No	1
45 46	35-44 18-24	Male	Unknown	Traumatic	No	No	res No	.NO Nu	No	1
40	10-24 55-64	Male	Non-Hispanic White	Nontraumatic	No	Ves	Yes	No	No	2
47	35.44	Female	Unknown	Traumatic	No	No	No	No	No	1
49	35-44	Female	Non-Hispanic White	Nontraumatic	No	No	Yes	Yes	Yes	1
50	35.44	Female	Non Hispanic White	Nontraumatic	No	No	Yes	No	Yes	1
51	55-64	Male	Non-Hispanic White	Traumatic	No	No	No	Yes	No	1
52	Over 65	Male	Non-Hispanic Black/African American	Traumatic	No	Yes	No	No	No	1
53	18-24	Male	Non-Hispanie White	Traumatie	No	No	No	No	No	2
54	Over 65	Female	Non-Hispanic White	Nontraumatic	Nu	No	No	Yes	No	2
55	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	Yes	Yes	Yes	ī
56	15 51	Male	Unknown	Nontraumatic	Yes	Yes	No	No	No	2
57	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	No	No	Yes	No	1
38	55-64	Male	Non-Hispanic White	Traumatic	No	No	No	Nu	No	3
59	55-64	Male	Unknown	Nontraumatic	No	No	Yes	Nu	No	1
60	25-34	Male	Unknown	Traumatic	No	No	Yes	No	Yes	3

428

429	Table 2. Demographics, Comorbidities, and Nerve Injuries.
430	
431	
432	
433	
434	

Patient ID	Site of Nerve Injury	Grade Pre-Treatment Intervention	Grade Post-Treatment Intervention	No Improvement	Small Improvement	Large Improvement
1	Left Radial	2 (LWE)	5 (LWE)	No	No	Yes
2	Right Ulnar	3 (RFAB)	4 (RFAB)	No	Yes	No
2	Right Median	2 (RFF)	1 (RFF)	No	No	Yes
2	Right Radial	0 (REE)	5 (REE)	No	No	Yes
7	Right Upper Trunk	4 (REF)	5 (REF)	No	No	Yes
9	Left C8 Root	4 (LWF)	5 (LWF)	No	No	Yes
10	Left Deep Peroneal	I (LADF)	4 (LADF)	No	No	Yes
11	Right Common Peroneal	0 (RAEV)	3 (RAEV)	No	No	Yes
12	Left Ulnar	2 (LFAB)	5 (LFAB)	No	No	Yes
12	Left Median	2 (LFF)	5 (LFF)	No	No	Yes
13	Right Upper Trunk	4 (REE)	5 (REE)	No	No	Yes
14	Right Spinal Accessory	1 (RSEL)	1 (RSEL)	No	No	Yes
14	Left Femoral	1 (LHF)	2 (LHF)	No	Yes	No
14	Left Obturator	4 (LHAD)	5 (LHAD)	No	No	Yes
16	Left Deep Peroneal	I (LADF)	3 (LADF)	No	No	Yes
16	Right Deep Peroneal	1 (RADF)	3 (RADF)	No	No	Yes
17	Right Scialic	0 (RAPF)	3 (RAPF)	No	No	Yes
17	Right Radial	0 (RWE)	3 (RWE)	No	No	Yes
18	Right Median	4 (RFF)	4 (RFF)	Yes	No	Ne
18	Right Upper Trunk	1 (REF)	1 (REF)	Yes	No	No
19	Right Common Peroneal	1 (RADF)	3 (RADF)	No	No	Yes
20	Right Femoral	2 (RHF)	5 (RHF)	No	No	Yes
20	Right Common Peroneal	1 (RADF)	4 (RADF)	No	No	Yes
21	Left C5 Root	3 (LEF)	4 (LEF)	No	Yes	No
22	Left Sciatic	4 (LKF)	5 (LKF)	No	No	Yes
23	Left Common Peroneal	0 (LGTE)	1 (LGTE)	No	Yes	No
24	Left Deep Peroneal	1 (LADF)	1 (LADF)	Yes	No	Ne
24	Left Sciatic	2 (LAIN)	1 (LAIN)	No	No	Yes
25	Left Lumbocacral Plexus	2 (LADF)	4 (LADF)	No	No	Yes
26	Left Radial	0 (LWE)	5 (LWE)	No	No	Yes
27	Right Common Peroneal	0 (RADF)	4 (RADF)	No	No	Yes
28	Left Sciatic	0 (LADF)	3 (LADF)	No	No	Yes
29	Right Posterior Cord	0 (RWE)	5 (RWE)	No	No	Yes
29	Right Middle Trunk	C (REE)	5 (REE)	No	No	Yes
29	Right Upper Trunk	0 (REF)	5 (REF)	No	No	Yes
30	Left Median	4 (LTF)	5 (LTF)	No	No	Yes
30	Right Ulnar	3 (RFAB)	5 (RFAE)	No	No	Yes
31	Left Radial	0 (LWE)	1 (LWE)	No	Yes	No
31	Left Middle Trunk	0 (LWE)	1 (LWE)	No	Yes	Ne
31	Right Middle Trunk	0 (REE)	4 (REE)	No	No	Yes
31	Left Upper Trunk	2 (LEF)	3 (LEF)	No	Yes	No
31	Right Upper Trunk	0 (REF)	4 (REF)	No	No	Yes
32	Left Deep Peroneal	1 (LADF)	4 (LADF)	No	No	Yes
33	Right Common Peroneal	1 (RADF)	1 (RADF)	Yes	Nu	No
33	Left Common Peroneal	1 (LADF)	3 (LADF)	No	No	Yes
34	Left Upper Trunk	0 (LWF)	3 (LWF)	No	No	Yes
34	Loft Middle Trunk	0 (LWE)	4 (LWE)	No	No	Yes
34	Left Lower Trunk	0 (LWF)	3 (LWF)	No	No	Yes
36	Right Upper Trunk	2 (REF)	5 (REF)	No	No	Yes
36	Right Radial	0 (RWE)	2 (RWE)	No	No	Yes
37	Left Suprascapular	2 (LSER)	5 (LSER)	No	No	Yes
38	Right Lateral Cord	2 (REF)	3 (REF)	No	Yes	Ne
39	Left C7 Root	0 (LFE)	2 (LFE)	No	No	Yes
39	Left C8 Roct	2 (LFAB)	2 (LFAB)	Yes	No	No
39	Left Radial	0 (LFF)	2 (LFE)	No	No	Yes
10	Right Radial	0 (RWE)	1 (RWE)	No	Yes	Ne
42	Left Femoral	C (LHF)	3 (LHF)	No	No	Yes
44	Right Radial	4 (REE)	5 (REE)	No	No	Yes
45	Right Deep Peroneal	4 (RADF)	5 (RADF)	No	No	Yes
46	Left Common Peroneal	0 (LADF)	1 (LADF)	No	Yes	No
47	Right Median	2 (RFF)	4 (RFF)	No	No	Yes
4/	Right Ulman	4 (RFAB)	1 (RFAB)	Yes	Nu	No
49	Left Radial	0 (LWE)	5 (LWE)	No	No	Yes
53	Right Sciatic	1 (RKF)	1 (RKF)	Yes	No	No
53	Left Common Peroneal	4 (LADF)	2 (LADF)	Yes	No	Ne
54	Left Sciatic	4 (LAPF)	4 (LAPF)	Yes	No	No
54	Left Femoral	1 (LHF)	0 (LHF)	Yes	No	No
11	Right Radial	0 (RWE)	2 (RWE)	No	No	Yes
58	Right Upper Trunk	0 (REF)	0 (REF)	Yes	No	No
58	Right Middle Trank	C (REE)	0 (REE)	Yes	Nu	Nu
58	Right Lower Trunk	0 (RFAB)	1 (RFAB)	No	Yes	No
59	Right Femoral	2 (RIT)	4 (RIIF)	No	No	Yes
60	Right Upper Trunk	C (REF)	1 (REF)	No	Yec	No
60	Right Middle Trunk	C (REE)	5 (REE)	No	No	Yes

436 437

Table 3. Manual Muscle Testing. Small Improvement (increase by one grade), Large Improvement

438 (Increase to 5 or increase by two or more grades); (LSEL)/(RSEL)- left/right shoulder elevators,
 439 (LEF)/(REF)- left/right elbow flexors, (LEE)/(REE)- left/right elbow extensors, (LWF)/(RWF)- left/right wrist

440 flexors, (LWE)/(RWE)- left/right wrist extensors, (LFF)/(RFF)- left/right finger flexors, (LFE)/(RFE)-

441 left/right finger extensors, (LFAB)/(RFAB)- left/right finger abductors, (LTF)/(RTF)- left/right thumb flexors,

442 (LHF)/(RHF)- left/right hip flexors, (LHAD)/(RHAD)- left/right hip adductors, (LKF)/(RKF)- left/right knee

443 flexors, (LADF)/(RADF)- left/right ankle dorsiflexors, (LAPF)/(RAPF)- left/right ankle plantarflexors,

444 (LAEV)/(RAEV)- left/right ankle evertors, (LGTE)/(RGTE)- left/right great toe extensors